Open in interactive viewer → charts, metric popovers & call review

Vylor's First Standalone Quarter Is a Loss — On Purpose

Corteva's seed spinoff posted a wider Q3 EBITDA loss and a shrinking top line, but the real headline is a licensing model that just crossed from seven years underwater into net-positive territory.
VYLR · Earnings Call · 2026-11-12

A bad quarter, carefully explained

On paper, Vylor's debut as a public company is easy to misread. Third-quarter net sales slipped 1% to $938 million, organic sales fell 3%, and operating EBITDA flipped to a $269 million loss — down 33% year over year. For a business that spent its September investor day selling a multi-year growth story, a shrinking top line and a deeper loss is an awkward coming-out party. Management's framing is that Q3 is the seed industry's dead zone. “we lose money most of the time because most farmers are in the field rather than making seed purchase decisions” — Charles Magro, Chief Executive Officer · 2026-11-12, Chuck Magro noted — so weather and shipment timing dominate a small quarter. But the bigger swing was self-inflicted: the deliberate migration of Brazil soybeans from a branded-seed model to a licensing business, which pulled roughly $50 million of revenue and volume out of Q3 and pushed the income into Q4. That is the crux of the volume declines the quarter reported — a deliberate trade, not lost demand.

The inflection that actually matters

The number worth circling is net licensing, which flipped positive. After more than a decade as a net payer of trait royalties, Magro was blunt: they had been

royalty neutral after 7 years and something like $700 million in the hole

Charles Magro, Chief Executive Officer · 2026-11-12
— and now expect to close 2026 roughly $60 million positive on about $180 million of net licensee fees. The stated ambition is $1 billion of net royalty income by 2035, and the September financial framework bakes in roughly $100 million a year of incremental licensing income. The reason this is credible rather than promotional sits in the structure of the Brazilian soy market, which David Johnson laid out plainly:

85% of the Brazil soy market is a licensing market and only 15% is branded. And we were going to market in that 15% as a branded business.

David Johnson, Chief Financial Officer · 2026-11-12
Walking away from the branded rump to chase the licensing majority is why margins matter more than volume here — “our margins are 3x higher in our licensing business in Brazil than our traditional branded business” — David Johnson, Chief Financial Officer · 2026-11-12. The engine is Conkesta, where trait penetration in Brazil has crossed the 10% threshold and is tracking toward ~12%. Corn is the bigger swing: corn licensing nearly doubled from 2025 to 2026, and the germplasm licensees already have in the ground could support another 40%-50% growth into 2027. The constraint is supply, not demand — “the problem that we've got right now is we are supply limited” — Charles Magro, Chief Executive Officer · 2026-11-12. The order book for Qrome triple-stack corn is described as very strong, unlocked five years early by the February settlement, but scaling a first-year production run takes time.

The third leg: hybrid wheat and gene editing

The longer-dated optionality is hybrid wheat, launching in 2027 on a proprietary production system Vylor calls Xpedite. Management claims up to 20% yield gains in dry conditions and 10% on average — the argument being that hybridization only works if you can produce seed cheaply enough that farmers still pay for the yield. The ambition is ~$500 million of revenue by 2035 and $1 billion by 2040, at which point “this becomes the third leg of the stool” — Charles Magro, Chief Executive Officer · 2026-11-12 alongside corn and soy. It is a global, branded-and-licensed business in the making, not just a North American product. Gene editing is the second long fuse. The EU parliament passed enabling legislation this year, with country-by-country implementation stretching through 2027 and possibly 2028, and China import approval for gene edited corn and soy still pending. Vylor's first candidate — a disease-resistant corn hybrid already cleared in the U.S. — is effectively ready, awaiting a decision on whether to launch in Europe or via a U.S. ethanol-crop stewarded release. None of this lands in the near-term numbers, but it is the pipeline the company is now promising to milestone publicly.

Framework, capital, and the fine print

The full-year guide was reaffirmed: ~$10.4 billion of revenue (+3%), ~$2.8 billion of operating EBITDA (+10%), roughly 27% EBITDA margin and $2.25-$2.35 of operating EPS. The 2027-2029 framework targets 3%-4% sales growth against 7%-8% EBITDA growth, a ~30% margin by 2029, ~60% free-cash conversion and about $1 billion a year of buybacks, ratable at roughly $250 million per quarter starting in Q1 2027. The balance sheet is a seasonal story. Net debt stood near $4.3 billion at quarter-end, but the Q4 cash harvest — receivables plus high-60s prepay rates — should bring in “a positive $3.5 billion to $4 billion” — David Johnson, Chief Financial Officer · 2026-11-12, leaving financial debt near $2.5 billion. Investors should also price in stand-alone realities: a 24%-26% base tax rate (higher than legacy Corteva, heavier Americas mix), higher 2027 interest expense as separation debt annualizes, and an EGL drag that normalizes once the hedge mismatch from the reverse-spin structure clears. One external check: the weather excuse is not company-unique. El Niño shows up across this reporting cycle — agricultural names like AVD and DOLE flagged it, and BAP walked through its risk assessment — so the top-line softness is a shared headwind, not a Vylor-specific failure. What is company-unique is the fix: a price for value strategy and a licensing pivot that trades reported volume for structurally higher margin. The quarterly optics look worse than the business; the question for the next two quarters is whether the promised Q4 margin catch-up shows up as cleanly as management insists. Even the databases haven't caught up — Vylor is still filed as a "Shell Company" days after listing a $48 billion seed franchise. On this call, the shell is the quarter, not the company.